ID

34473

Description

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach; ODM derived from: https://clinicaltrials.gov/show/NCT01138527

Link

https://clinicaltrials.gov/show/NCT01138527

Keywords

  1. 1/17/19 1/17/19 -
  2. 5/27/19 5/27/19 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 17, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT01138527

Eligibility Prostate Cancer NCT01138527

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy-proven diagnosis of adenocarcinoma of the prostate
Description

ID.1

Data type

boolean

subject will sign a consent form prior to study entry
Description

ID.2

Data type

boolean

radical prostatectomy and histopathological exam planned
Description

ID.3

Data type

boolean

the time interval between last biopsy and the mr exam must be at least 4 weeks
Description

ID.4

Data type

boolean

the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are unable to give valid informed consent
Description

ID.6

Data type

boolean

subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
Description

ID.7

Data type

boolean

therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
Description

ID.8

Data type

boolean

patients under hormone deprivation therapy.
Description

ID.9

Data type

boolean

Similar models

Eligibility Prostate Cancer NCT01138527

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
biopsy-proven diagnosis of adenocarcinoma of the prostate
boolean
ID.2
Item
subject will sign a consent form prior to study entry
boolean
ID.3
Item
radical prostatectomy and histopathological exam planned
boolean
ID.4
Item
the time interval between last biopsy and the mr exam must be at least 4 weeks
boolean
ID.5
Item
the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
subjects who are unable to give valid informed consent
boolean
ID.7
Item
subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
boolean
ID.8
Item
therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
boolean
ID.9
Item
patients under hormone deprivation therapy.
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial